The Agency for Science, Technology and Research (A*STAR) and the National University of Singapore (NUS) signed a Memorandum of Understanding (MOU) with three leading pharmaceutical companies to mark the launch of an initiative to develop the country’s pharma manufacturing sector. Named the Pharma Innovation Programme Singapore (PIPS), the initiative involved pioneer partners GSK, MSD International, and Pfizer Asia Pacific.
PIPS will focus on areas such as continuous manufacturing, bio-catalysis, process analytical technology and advanced process control. It will bring together Singapore’s public sector research capabilities and the domain expertise of key players in the Pharma industry to improve and transform the manufacturing operations and technologies of the industry.
The MOU was endorsed at the inaugural Future of Manufacturing (FoM) Summit held on 5 September 2017.